雷公藤多苷片联合环磷酰胺治疗自身免疫性溶血性贫血的临床研究-现代医学

雷公藤多苷片联合环磷酰胺治疗自身免疫性溶血性贫血的临床研究

单位：1. 宝鸡市人民医院血液肿瘤风湿科, 陕西宝鸡 721004;
2. 解放军第三医院血液科, 陕西宝鸡 721004

分类号：R556.6

出版年·卷·期（页码）：2020·48·第二期（222-225）

摘要：

目的： 研究雷公藤多苷片联合环磷酰胺治疗自身免疫性溶血性贫血的疗效。方法： 选取我院2014年12月至2017年12月收治的80例自身免疫性溶血性贫血患者作为研究对象，随机分为两组，每组各40例。对照组给予环磷酰胺，观察组患者患者在此基础上每日给予雷公藤多苷片。比较两组患者在治疗后的临床疗效、复发率和不良反应的发生率以及在治疗前后疾病相关指标水平。结果： 经过治疗后，两组患者疾病控制率相比较，观察组显著高于对照组，差异具有统计学意义（P<0.05）；在治疗一年后，两组患者疾病复发率相比较，观察组显著低于对照组，差异具有统计学意义（P<0.05）；两组患者的LDH、TBil和MCH水平显著优于治疗前，差异具有统计学意义（P<0.05）；观察组各项指标改善程度显著优于对照组，差异具有统计学意义（P<0.05）。结论： 采用雷公藤多苷片联合环磷酰胺治疗自身免疫性溶血性贫血，具有较好的临床疗效，能够有效缓解并改善患者临床症状，降低治疗后复发，改善患者疾病相关指标，安全性较高，值得临床推广。

Objective: To study the effect of tripterysium glycosides combined with cyclophosphamide in treatment of autoimmune hemolytic anemia. Methods: The 120 patients with autoimmune hemolytic anemia from December 2014 to December 2017 were selected and randomly divided into two groups, 60 in each group.The control group was given cyclophosphamide. The treatment group was given tripterysium glycosides combined with cyclophosphamide. The treatment effect, recurrence rate and incidence of adverse reactions after treatment were compared;The serum correlation index before and after treatment were compared. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group. The difference between the two groups was statistically significant (P<0.05).The recurrence rate of the observation group was significantly lower than that of the control group. The difference between the two groups was statistically significant (P<0.05) one year after treatment.The levels of LDH,TBil and MCH in the two groups were significantly higher than those before treatment. The difference between the two groups was statistically significant (P<0.05).The improvement of the observation group was significantly higher than that of the control group. The difference between the two groups was statistically significant (P<0.05). Conclusion: Tripterysium glycosides combined with cyclophosphamide treating autoimmune hemolytic anemia has good clinical curative effect, and can significantly improve the patient's clinical symptoms and reduce recurrence after treatment.It is worthy for clinical promotion for its safety.

参考文献：

[1] 曲莹莹,邢莉民,邵宗鸿.T淋巴细胞在自身免疫性溶血性贫血发病机制中的作用[J].国际输血及血液学杂志,2017,40(5):234-237.
[2] 王化泉,邢莉民,邵宗鸿.自身免疫性溶血性贫血的治疗进展[J].中华医学杂志,2016,96(26):2111-2114.
[3] 贡蓉,贺少龙,王涛,等.环磷酰胺联合环孢素治疗输血依赖的MDS 5q合并自身免疫性溶血性贫血一例[J].山西医药杂志,2017,46(23):2962-2963.
[4] 李金全,运乃茹,温学红.雷公藤多苷在常见自身免疫性疾病中的临床应用及安全性[J].医学综述,2016,22(19):3850-3854.
[5] 曹海武,赵晓红,陆时运,等.利妥昔单抗联合丙种球蛋白治疗复发难治性自身免疫性溶血性贫血疗效观察[J].海南医学,2016,27(22):3637-3639.
[6] 金伟媚,江锦红,方炳木.利妥昔单抗联合常规治疗自身免疫性溶血性贫血的疗效观察[J].药物流行病学杂志,2017,6(4):230-233.
[7] 高清妍,张凤奎.自身免疫性溶血性贫血研究进展[J].中华血液学杂志,2016,37(11):1012-1016.
[8] 解飞,周霖,蔡斌,等.儿童自身免疫性溶血性贫血29例临床特点和治疗分析[J].临床儿科杂志,2016,34(12):930-932.
[9] 黄轶群,郑瑞玑,吴荣娟,等.美罗华联合自体造血干细胞移植治疗伴有自身免疫性溶血性贫血的CD5阳性弥漫大B细胞淋巴瘤[J].中国实验血液学杂志,2016,24(3):722-726.
[10] 王烨,陈勤奋.免疫抑制剂在血液系统疾病治疗中的应用[J].上海医药,2016,37(1):16-20.
[11] 黄振东,施均,邵英起,等.12例伴单克隆免疫球蛋白Mκ血症的自身免疫性溶血性贫血患者临床分析[J].中华血液学杂志,2016,37(3):233-237.
[12] 尚瑞,吴军.雷公藤多甙、硫唑嘌呤联合甘草酸二铵治疗自身免疫性肝炎患者初步临床研究[J].实用肝脏病杂志,2017,20(3):290-293.
[13] 张玲娟.优思弗联合雷公藤多苷治疗原发性胆汁性肝硬化的临床疗效观察[D].长春:吉林大学,2015.
[14] 田华,王金波,冯万周.LDH及sTfR在成人急性溶血性贫血中的意义[J].标记免疫分析与临床,2016,23(6):691-692.
[15] 刘善浩,何合胜.自身免疫性溶血性贫血患者胆红素特点的分析[J].皖南医学院学报,2017,36(3):237-239.
[16] 陈宝龙.不同输血方法在自身免疫性溶血性贫血患者中的应用研究[J].当代医学,2016,22(30):97-98.
[17] 丁琴丽,陈宝龙,邱芳,等.产生类抗体的自身免疫性溶血性贫血患者的输血选择[J].中国实验血液学杂志,2017,25(4):1208-1211.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录